相似文献
1
The impact of cytomegalovirus infection ≥1 year after primary renal transplantation.
Clin Transplant. 2010 Jul-Aug;24(4):572-7. doi: 10.1111/j.1399-0012.2010.01208.x.
2
Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience.
Nephrol Dial Transplant. 2013 Mar;28(3):758-65. doi: 10.1093/ndt/gfs531. Epub 2012 Dec 14.
3
The impact of early cytomegalovirus infection after kidney transplantation on long-term graft and patient survival.
Clin Transplant. 2014 Jan;28(1):120-6. doi: 10.1111/ctr.12288. Epub 2013 Dec 18.
4
Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: A paired kidney analysis.
Am J Transplant. 2019 Feb;19(2):573-584. doi: 10.1111/ajt.15183. Epub 2018 Dec 14.
5
Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
Int J Infect Dis. 2017 Dec;65:50-56. doi: 10.1016/j.ijid.2017.09.023. Epub 2017 Oct 3.
6
Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.
Clin Transplant. 2013 Jul-Aug;27(4):503-9. doi: 10.1111/ctr.12138. Epub 2013 Jun 3.
7
Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
Transplantation. 2010 Nov 27;90(10):1091-8. doi: 10.1097/TP.0b013e3181f7c053.
8
Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival.
Kidney Int. 2004 Jul;66(1):329-37. doi: 10.1111/j.1523-1755.2004.00735.x.
9
Revisiting cytomegalovirus serostatus and replication as risk factors for inferior long-term outcomes in the current era of renal transplantation.
Nephrol Dial Transplant. 2020 Feb 1;35(2):346-356. doi: 10.1093/ndt/gfz268.
10
Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection.
Pediatr Transplant. 2008 Jun;12(4):474-8. doi: 10.1111/j.1399-3046.2007.00781.x.
引用本文的文献
1
Bridging the gap: assessing CMV DNAemia in kidney transplant recipients with previous solid organ transplants.
Front Transplant. 2024 Apr 9;3:1280280. doi: 10.3389/frtra.2024.1280280. eCollection 2024.
2
A Decade-Long Cohort Analysis of Human Cytomegalovirus (HCMV)-Induced Early and Late Renal Rejection in Post-Transplant Patients in the Eastern Indian Population.
Viruses. 2024 May 25;16(6):847. doi: 10.3390/v16060847.
3
The pattern of cytomegalovirus replication in post-renal transplant recipients with pre-emptive therapy strategy during the 1 year of post-transplantation.
Int J Health Sci (Qassim). 2023 Sep-Oct;17(5):39-44.
4
Long-term CMV monitoring and chronic rejection in renal transplant recipients.
Front Cell Infect Microbiol. 2023 Jun 13;13:1190794. doi: 10.3389/fcimb.2023.1190794. eCollection 2023.
5
CMV specific T cell immune response in hepatitis C negative kidney transplant recipients receiving transplant from hepatitis C viremic donors and hepatitis C aviremic donors.
Ren Fail. 2022 Dec;44(1):831-841. doi: 10.1080/0886022X.2022.2072744.
6
Assessment of Risk Factors and Outcome of Early Versus Late Cytomegalovirus Infection Infection in Living-related D+/R + Renal Allograft Recipients.
Indian J Nephrol. 2022 Jan-Feb;32(1):47-53. doi: 10.4103/ijn.IJN_463_20. Epub 2021 Mar 27.
7
Cytomegalovirus Infection after Renal Transplantation: Occurrence, Clinical Features, and the Cutoff for Antigenemia in a University Hospital in Brazil.
Infect Chemother. 2017 Dec;49(4):255-261. doi: 10.3947/ic.2017.49.4.255.
8
Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
BMC Infect Dis. 2017 Jul 17;17(1):501. doi: 10.1186/s12879-017-2599-y.
9
Very-late-onset cytomegalovirus disease: a case-report and review of the literature.
BMC Res Notes. 2017 Jun 13;10(1):210. doi: 10.1186/s13104-017-2532-x.
10
IL-23 plasma level is strongly associated with CMV status and reactivation of CMV in renal transplant recipients.
BMC Immunol. 2016 Oct 3;17(1):35. doi: 10.1186/s12865-016-0175-7.
本文引用的文献
1
Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation.
Clin Infect Dis. 2008 Mar 15;46(6):840-6. doi: 10.1086/528718.
2
Delayed-onset primary cytomegalovirus disease after liver transplantation.
Liver Transpl. 2007 Dec;13(12):1703-9. doi: 10.1002/lt.21280.
3
Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.
Am J Transplant. 2008 Jan;8(1):69-77. doi: 10.1111/j.1600-6143.2007.02031.x. Epub 2007 Oct 31.
4
Cytomegalovirus in transplantation - challenging the status quo.
Clin Transplant. 2007 Mar-Apr;21(2):149-58. doi: 10.1111/j.1399-0012.2006.00618.x.
5
Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis.
Transplantation. 2006 Jun 27;81(12):1645-52. doi: 10.1097/01.tp.0000226071.12562.1a.
6
7
Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis.
Transplantation. 2004 Nov 15;78(9):1390-6. doi: 10.1097/01.tp.0000145989.22373.03.
8
Late cytomegalovirus disease with atypical presentation in renal transplant patients: case reports.
Transplant Proc. 2004 Jul-Aug;36(6):1841-3. doi: 10.1016/j.transproceed.2004.07.017.
9
Evolution of immunosuppression at the University of Minnesota.
Transplant Proc. 2004 Mar;36(2 Suppl):64S-70S. doi: 10.1016/j.transproceed.2004.01.062.
10
Late cytomegalovirus disease following liver transplantation.
Transpl Int. 2003 Dec;16(12):861-5. doi: 10.1007/s00147-003-0643-x. Epub 2003 Aug 5.
Zotero 插件